Chronic Kidney Disease & Electrolytes • ICD-10-CM E87.1
Sodium - low (hyponatremia)
Also known as: Hyponatremia
Audited by the DotMD AI Specialist Council
•
FDA DailyMed SPL: 2026-11-02 • ICD-10-CM E87.1 • 8 Linked .gov / PubMed Citations
•
Governance: Dr. Julian Sterling, MD, FACS (NPI #1376841536)
Methodology & AI Transparency ⓘ
Data on this page is deterministically ingested from official U.S. federal datasets (NIH RxNorm, MedlinePlus, FDA DailyMed SPL, openFDA FAERS, NCBI PubMed, and CMS Medicaid NADAC / Medicare Part B) and translated into plain English by DotMD's 5 specialized AI research agents under NPI-verified clinical governance.
At a Glance • Plain-English Clinical Summary
Sodium - low (hyponatremia) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Clinical triage of Sodium - low (hyponatremia) (also termed Hyponatremia) (E87.1) in Kidney & Renal relies on serial eGFR (creatinine in Sodium - low (hyponatremia) (E87.1: + cystatin C)), guiding step-wise therapeutic adjustments toward Urine Albumin-to-Creatinine Ratio in Sodium - low (hyponatremia) (E87.1: (uACR)) (< 15 mg/g (< 30 mg/g normal) (E87.1)).
- 2 Real-world patient consensus: Diagnostic registry E87.1: Sodium - low (hyponatremia) is managed within Kidney & Renal (aka Hyponatremia).
- 3 Typical cash cost range: Clinicians assessing Sodium - low (hyponatremia) focus on erythropoietin decline [Sodium - low (hyponatremia) E87.1] and targeted history.
- 4 Top reported side effects / signs: Objective lab/clinical target for Sodium - low (hyponatremia): eGFR (Creatinine + in Sodium - low (hyponatremia) (E87.1: Cystatin C)) (>= 90 mL/min/1.73m2 (E87.1)) and Urine Albumin-to-Creatinine Ratio in Sodium - low (hyponatremia) (E87.1: (uACR)).
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data
3 of 3 Free Questions RemainingAsk our AI Specialists anything about Sodium - low (hyponatremia)
What Is Sodium - low (hyponatremia)?
Clinical triage of Sodium - low (hyponatremia) (also termed Hyponatremia) (E87.1) in Kidney & Renal relies on serial eGFR (creatinine in Sodium - low (hyponatremia) (E87.1: + cystatin C)), guiding step-wise therapeutic adjustments toward Urine Albumin-to-Creatinine Ratio in Sodium - low (hyponatremia) (E87.1: (uACR)) (< 15 mg/g (< 30 mg/g normal) (E87.1)).
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Sodium - low (hyponatremia) (ICD-10 E87.1) is driven by erythropoietin decline [Sodium - low (hyponatremia) E87.1]; specialists in Chronic Kidney Disease & Electrolytes monitor Urine Albumin-to-Creatinine Ratio in Sodium - low (hyponatremia) (E87.1: (uACR)) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Sodium - low (hyponatremia) (E87.1): fluid retention in in Sodium - low (hyponatremia) (E87.1: ankles, hands, or)
- • Secondary Sodium - low (hyponatremia) clinical sign: fatigue, muscle cramps, in Sodium - low (hyponatremia) (E87.1: metallic taste, or)
- • Symptom flares in Sodium - low (hyponatremia) correlating with eGFR (Creatinine + in Sodium - low (hyponatremia) (E87.1: Cystatin C)) deviation outside >= 90 mL/min/1.73m2 (E87.1)
- • Functional kidney & renal impact requiring serial eGFR (creatinine in Sodium - low (hyponatremia) (E87.1: + cystatin C)) evaluation (E87.1)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Sodium - low (hyponatremia) Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E87.1 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Chronic Kidney Disease & Electrolytes | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: eGFR (Creatinine + in Sodium - low (hyponatremia) (E87.1: Cystatin C)) | >= 90 mL/min/1.73m2 (E87.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Urine Albumin-to-Creatinine Ratio in Sodium - low (hyponatremia) (E87.1: (uACR)) | < 15 mg/g (< 30 mg/g normal) (E87.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Potassium, Bicarbonate in Sodium - low (hyponatremia) (E87.1: & Phosphorus) | K+ 3.8–4.8 mEq/L; HCO3 23–29 mEq/L (E87.1) | Clinical Reference Target Range |
Marcus Sterling (AI Healthcare Price Auditor) & Dr. Vance
Check Drug Interactions →
FDA-Monographed Medications & Public Cash Price Reference for Sodium - low (hyponatremia)
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Sodium Iothalamate I-125 Injection Glofil-125 • RxCUI RXN-509147729-2357 | Radioactive Diagnostic Agent | 91% | $2.2100 | $ 98.00 /mo |
| Dalteparin Sodium Fragmin • RxCUI RXN-00690206-2463 | Anti-coagulant | 85% | $3.2200 | $ 138.91 /mo |
| Treximet (Sumatriptan Succinate and Naproxen Sodium) Treximet • RxCUI 849450-B42847850 | Nonsteroidal Anti-inflammatory Drug | 86% | $16.3139 | $ 185.70 /mo |
| Dexmedetomidine Hydrochloride in Sodium Chloride Dexmedetomidine Hydrochloride in Sodium Chloride Generic • RxCUI RXN-701211712-2974 | Central alpha-2 Adrenergic Agonist | 94% | $2.3800 | $ 104.89 /mo |
| Pantoprazole Sodium in 0.9% Sodium Chloride Pantoprazole Sodium in 0.9% Sodium Chloride Generic • RxCUI RXN-03389648-2569 | Proton Pump Inhibitor | 84% | $4.1626 | $ 177.09 /mo |
| Betaloan Suik (Betamethasone Sodium Phosphate and Betamethasone Acetate) Betaloan Suik • RxCUI RXN-B76420240 | Corticosteroid | 94% | $0.4312 | $ 39.55 /mo |
| Nipride Rtu (Sodium Nitroprusside) Nipride Rtu • RxCUI 1876373 | Vasodilator | 85% | $0.8800 | $ 71.86 /mo |
| Invokana (Canagliflozin) Invokana • RxCUI 1373463 | Sodium-Glucose Cotransporter 2 Inhibitor | 88% | $19.1169 | $ 640.00 /mo |
| Emetrol Chewables Orange (Sodium Citrate Dihydrate) Emetrol Chewables Orange • RxCUI 2002800 | Anti-coagulant | 88% | $1.0700 | $ 85.54 /mo |
| Ceftobiprole Medocaril Sodium Zevtera • RxCUI RXN-68547578-2422 | Cephalosporin Antibacterial | 81% | $2.8600 | $ 124.33 /mo |
| Sodium Oxybate Lumryz, Xyrem • RxCUI 349482 | Central Nervous System Depressant | 92% | $3.5100 | $ 150.66 /mo |
| Depakote (Divalproex Sodium) Depakote • RxCUI 1099625-B00747325 | Anti-epileptic Agent | 76% | $1.9587 | $ 6.14 /mo |
| Levetiracetam in Sodium Chloride Levetiracetam in Sodium Chloride Generic • RxCUI 1193358 | Decreased Central Nervous System Disorganized Electrical Activity | 90% | $0.1663 | $ 15.24 /mo |
| Heparin Sodium Heparin Sodium Generic • RxCUI 1361574 | Anti-coagulant | 80% | $7.6218 | $ 185.00 /mo |
| Sutab (Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride) Sutab • RxCUI RXN-B24338201 | Calculi Dissolution Agent | 75% | $6.7203 | $ 492.36 /mo |
| Allopurinol Sodium Zyloprim • RxCUI 197319 | Xanthine Oxidase Inhibitor | 78% | $0.0366 | $ 5.59 /mo |
Dr. Lin (AI PubMed Clinical Trial Lead)
Browse All PubMed Translations →
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Sodium - low (hyponatremia))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Rosuvastatin and atorvastatin on kidney function:: What a 24,278-Participant Study Found Both RSV and ATV improve GFR, and ATV seems to be more effective in reducing proteinuria. Circulation journal : official journal of the Japanese Circulation Society • 2012-01-15 • Meta-Analysis | N = 24,278 | 99/100 | PMID 22382383 ↗ |
| New Insights on Benefits and safety of 11 sodium-glucose cotransporter-2 inhibitors at different: What a 9,144-Participant Study Found As add-on therapy, SGLT2is demonstrated favourable antidiabetic efficacy and acceptable safety. BMJ open • 2025-02-26 • Meta-Analysis | N = 9,144 | 99/100 | PMID 40010842 ↗ |
| Check Your Medicine Cabinet: FDA Enforcement Recall D-0039-2027 (Class II): Hydrocortisone Sodium Succinate for Injec Reason for Recall (Class II): Failed Impurities/Degradation Specifications. openFDA Drug Enforcement & Recall Registry • 2026-10-21 • FDA Drug Recall (Class II) | Multi-cohort | 96/100 | PMID FDARECALL-D-0039-2027 ↗ |
| New Insights on Sodium-Glucose Co-Transporter 2 Inhibitors Compared with Sulfonylureas in: What a 4,300-Participant Study Found Despite similar glycemic efficacy in a relatively short term, SGLT2 inhibitors are more effective in the longer term than SUs as add-on to metformin. Clinical drug investigation • 2019-06-15 • Meta-Analysis | N = 4,300 | 94/100 | PMID 31041606 ↗ |
| New Insights on Prostacyclin analog beraprost sodium efficacy in primary glomerular disease or: What a 892-Participant Study Found TRK-100STP was generally well tolerated and most adverse drug reactions were mild or moderate in severity. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy • 2021-10-15 • Phase III Randomized Trial | N = 892 | 93/100 | PMID 33340238 ↗ |
Zero-PHI Patient Support & Cohort Discussions
Sodium - low (hyponatremia) Patient Community & “People Like Me” Threads
“People Like Me” Cohort Filter (Zero-PHI)
Filter Sodium - low (hyponatremia) community threads and patient logs by age, biological sex, dosage, and treatment duration.
No threads match this cohort filter yet. Click + Start Anonymous Discussion to ask the community about Sodium - low (hyponatremia).